Phase 3 miss, rights reacquired, NDA filed anyway — approvability on marginal data is the only question that matters

Gossamer Bio is a clinical-stage company developing an inhaled targeted respiratory drug for pulmonary arterial hypertension that is not yet approved, despite having filed for FDA review after its pivotal trial narrowly missed its primary goal.

Gossamer's seralutinib, an inhaled kinase inhibitor for pulmonary arterial hypertension, narrowly missed its Phase 3 primary endpoint, yet FDA characterized the statistical shortfall as a review issue rather than a filing barrier. The thesis rests entirely on whether FDA will approve a drug whose pivotal trial missed its prespecified alpha threshold, supported by favorable secondary endpoints and a subgroup signal. With $57M in cash and a burn rate implying runway into Q1 2027, the company likely cannot survive past an NDA filing without additional capital.